Harvard Business Review

JANUARY 5, 2012

For the past few decades, emerging technologies such as biotechnology, microelectronics, information technology and communications technologies have become central to the socioeconomic development of nations. IT is good for developing countries — it empowers people and improves their lives. The farms are now IT labs.

Information Technology 15

Information Technology Technology Information Trends 15

Harvard Business Review

OCTOBER 26, 2011

Despite these gloomy headlines, three developments in the sector give us hope that the revolution in clean energy production is far from dead: 1. Their behavior displays promising parallels to the early days of the biotechnology industry.

Energy 11

Energy Finance IPO Biotechnology 11

Harvard Business Review

SEPTEMBER 21, 2018

This isn’t all that surprising given the level of innovation activity in these sectors, but directors operating in similarly disrupted sectors should take note. Just over one-fifth (22%) of boards operating in the IT and telecom industry sought tech expertise when filling their most recent board seat, higher than in any other industry.

Innovation 10

Innovation Short-term Telecommunications Long-term 10

Harvard Business Review

JUNE 4, 2018

” “Our goal,” it stated, “must be to develop the talents of all to their fullest.” The talents of all are not being developed to their fullest, and many U.S. operational headquarters in Lexington, Massachusetts, which has been working with nearby Quincy College for the past several years.

Education 8

Education Company Biotechnology Human Capital 8

Harvard Business Review

FEBRUARY 17, 2011

The reason for the interest in in part because the industry has suffered from poor returns on investment over the last decade; indeed, some sectors, including biotechnology, report negative aggregate returns. Because of three significant challenges innovators face in emerging markets: Innovation ecosystems are not well-developed.

Marketing 15

Marketing Venture Capitalist Biotechnology IPO 15

Harvard Business Review

MAY 1, 2014

I learned this while leading a turnaround of NPS Pharmaceuticals , a biotechnology company that now specializes in creating treatments for rare diseases. To save the 20-year-old company, I had to get it operating like a start-up. In the process, I came up with six rules that could also help others change their cultures.

Company 9

Company Pharmaceuticals Biotechnology Short-term 9

Harvard Business Review

SEPTEMBER 14, 2011

Chirotech specializes in biocatalysis and chemocatalysis, two important subspecialties of biotechnology and chemistry that help develop key biological and chemical intermediates needed for the efficient production of medicines. You can't run your global R&D operations from headquarters in Mumbai. and the U.K.

Globalization 9

Globalization Innovation Decentralization Chemicals 9

Harvard Business Review

OCTOBER 23, 2014

Used to its full potential, this is predictive medicine — the ability to integrate and analyze known disease characteristics with a specific patient’s history and health status, and use the resulting insights to change outcomes and inform new directions for life sciences research and development. They’re also sharing risk.

Health Care 8

Health Care Pharmaceuticals Information Technology Supply Chain 8

Harvard Business Review

JUNE 16, 2016

The Joint Center For Energy Storage Research (JCESR) has a five-year mandate to develop next generation battery technologies. “But here, we can operate within the time frame of the next coffee break.” Firms have also invested additional money to build facilities near the hubs to better integrate their operations with them.

Technology 8

Technology Venture Capitalist Supply Chain Innovation 8

Harvard Business Review

MARCH 17, 2014

Under the broad umbrella of impact investments lie myriad sectors, asset types, and investment products, most of which still need to be developed and understood. First, impact investing needs time to develop. Impact Investing in the Future: Developed clusters across the spectrum. sanitation, housing, mobile banking).

Development 8

Development Microfinance Biotechnology Exit Strategy 8

Harvard Business Review

FEBRUARY 3, 2015

By managing the three key properties of networks that either propel you forward or hold you back—breadth, connectivity, and dynamism—you can develop a stronger network and use it as an essential leadership tool. The result was that their ideas were not developed. The good news is that you can change that.

How To 8

How To Diversity Letter Learning-by-Doing 8

Harvard Business Review

MARCH 5, 2012

Indian companies, for instance, are already doing quite well exporting services like software development, technical support, and back-office processing to America. This tight connection between R&D, innovation, and production is present in sectors like biotechnology, advanced materials, and nanotechnology. But let's not kid ourselves.

Health Care 9

Health Care Biotechnology Industry Policies 9

Harvard Business Review

MARCH 30, 2017

The AEM cube, a tool developed by Peter Robertson, a psychiatrist and business consultant, assesses differences in the way people approach change. We worked with a startup biotechnology company. It cannot be predicted or easily orchestrated. When its R&D team members tried our strategy execution task, they performed terribly.

Diversity 8

Diversity Team Biotechnology Execution 8

Harvard Business Review

JULY 22, 2015

.” Hanguk was a large, fast-growing company with diversified interests spanning electronics, biotechnology, shipping, construction, and chemicals. Its most successful division, mobile telephony, was looking for a new head of software development at headquarters in Seoul. I’ll have 25 developers reporting to me.”

Case Study 8

Case Study Career Biotechnology Course 8

Harvard Business Review

SEPTEMBER 11, 2014

For example, a wide variety of clean technologies (including wind, solar, and hydrogen) are vying to power vehicles and cities at the same time that a wide variety of medical technologies (chemical, biotechnological, genomic, and robotic) are being developed to treat diseases. Consider the 2×2 matrix below.

Uncertainty 22

Uncertainty Industry Bottom-up Technology 22

Harvard Business Review

AUGUST 23, 2016

Boards of companies operating in the consumer discretionary industry have a disproportionately high representation of Democrats, while boards operating in the industrials and energy and utilities industries skew more Republican. pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g.,

Politics 8

Politics Committee Telecommunications Diversity 8